Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Laboratory evaluation of SARS-CoV-2 antibodies: detectable IgG up to 20 weeks post infection

Louise J. Robertson, Julie S. Moore, Kevin Blighe, Kok Yew Ng, Nigel Quinn, Fergal Jennings, Gary Warnock, Peter Sharpe, Mark Clarke, Kathryn Maguire, Sharon Rainey, Ruth Price, William Burns, Amanda Kowalczyk, Agnes Awuah, Sara McNamee, Gayle Wallace, David Hunter, Steve Segar, Connie Chao Shern, M. Andrew Nesbit, James McLaughlin, Tara Moore
doi: https://doi.org/10.1101/2020.09.29.20201509
Louise J. Robertson
1Biomedical Sciences Research Institute, Ulster University, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie S. Moore
1Biomedical Sciences Research Institute, Ulster University, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Blighe
1Biomedical Sciences Research Institute, Ulster University, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kok Yew Ng
2Nanotechnology and Integrated Bioengineering Centre, Ulster University, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nigel Quinn
3Clinical Biochemistry Laboratory, Southern Health and Social Care Trust, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fergal Jennings
3Clinical Biochemistry Laboratory, Southern Health and Social Care Trust, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Warnock
4Microbiology Laboratory, Southern Health and Social Care Trust, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Sharpe
3Clinical Biochemistry Laboratory, Southern Health and Social Care Trust, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Clarke
5Northern Ireland Blood Transfusion Service, Belfast City Hospital, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathryn Maguire
5Northern Ireland Blood Transfusion Service, Belfast City Hospital, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon Rainey
5Northern Ireland Blood Transfusion Service, Belfast City Hospital, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth Price
1Biomedical Sciences Research Institute, Ulster University, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Burns
2Nanotechnology and Integrated Bioengineering Centre, Ulster University, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Kowalczyk
1Biomedical Sciences Research Institute, Ulster University, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agnes Awuah
1Biomedical Sciences Research Institute, Ulster University, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara McNamee
2Nanotechnology and Integrated Bioengineering Centre, Ulster University, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gayle Wallace
6Royal Victoria Hospital, Belfast Health and Social Care Trust, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Hunter
6Royal Victoria Hospital, Belfast Health and Social Care Trust, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve Segar
1Biomedical Sciences Research Institute, Ulster University, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Connie Chao Shern
7Avellino, 1505 Adams Dr, Menlo Park, CA 94025, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Andrew Nesbit
1Biomedical Sciences Research Institute, Ulster University, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James McLaughlin
2Nanotechnology and Integrated Bioengineering Centre, Ulster University, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tara.moore@ulster.ac.uk jad.mclaughlin@ulster.ac.uk
Tara Moore
1Biomedical Sciences Research Institute, Ulster University, Northern Ireland
7Avellino, 1505 Adams Dr, Menlo Park, CA 94025, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tara.moore@ulster.ac.uk jad.mclaughlin@ulster.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The SARS-CoV-2 pandemic necessitated rapid and global responses across all areas of healthcare, including an unprecedented interest in serological immunoassays to detect antibodies to the virus. The dynamics of the immune response to SARS-CoV-2 is still not well understood and requires further investigation into the longevity of humoral immune response that is evoked due to SARS-CoV-2 infection.

Methods We measured SARS-CoV-2 antibody levels in plasma samples from 880 people in Northern Ireland using Roche Elecsys Anti-SARS-CoV-2 IgG/IgA/IgM, Abbott SARS-CoV-2 IgG and EuroImmun IgG SARS-CoV-2 ELISA immunoassays to analyse immune dynamics over time. We undertook a laboratory evaluation for the UK-RTC AbC-19 rapid lateral flow immunoassay (LFIA), for the target condition of SARS-CoV-2 Spike protein IgG antibodies using a reference standard system to establish a characterised panel of 330 positive and 488 negative SARS-CoV-2 IgG samples.

Results We detected persistence of SARS-CoV-2 IgG up to 140 days (20 weeks) post infection, across all three laboratory-controlled immunoassays. On the known positive cohort, the UK-RTC AbC-19 lateral flow immunoassay showed a sensitivity of 97.58% (95.28%-98.95%) and on known negatives, showed specificity of 99.59% (98.53 %-99.95%).

Conclusions Through comprehensive analysis of a cohort of pre-pandemic and pandemic individuals, we show detectable levels of IgG antibodies, lasting up to 140 days, providing insight to antibody levels at later time points post infection. We show good laboratory validation performance metrics for the AbC-19 rapid test for SARS-CoV-2 Spike protein IgG antibody detection in a laboratory based setting.

Competing Interest Statement

At the time of this study TM and JML acted as advisors to CIGA HealthCare, an industrial partner in the UK Rapid Test Consortium. No personal financial reward or renumeration was received for this advisory role. At the time of submission of this manuscript TM and JML no longer held these advisory positions. All other authors have no potential conflict of interest to report.

Funding Statement

Costs for assays and laboratory expenses only will be paid by UK-RTC as is normal practice. The authors have not been paid or financially benefitted from this study. The advisory roles within CIGA Healthcare were unpaid temporary roles. This manuscript and associated data within this paper has only been used to build confidence into the overall device design and performance assessment of the UK RTC AbC-19 devices and such work was never commissioned for any government contractual consideration.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by Ulster University Institutional Ethics committee (REC/20/0043), South Birmingham REC (The PANDEMIC Study IRAS Project ID: 286041Ref 20/WM/0184).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted November 19, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Laboratory evaluation of SARS-CoV-2 antibodies: detectable IgG up to 20 weeks post infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Laboratory evaluation of SARS-CoV-2 antibodies: detectable IgG up to 20 weeks post infection
Louise J. Robertson, Julie S. Moore, Kevin Blighe, Kok Yew Ng, Nigel Quinn, Fergal Jennings, Gary Warnock, Peter Sharpe, Mark Clarke, Kathryn Maguire, Sharon Rainey, Ruth Price, William Burns, Amanda Kowalczyk, Agnes Awuah, Sara McNamee, Gayle Wallace, David Hunter, Steve Segar, Connie Chao Shern, M. Andrew Nesbit, James McLaughlin, Tara Moore
medRxiv 2020.09.29.20201509; doi: https://doi.org/10.1101/2020.09.29.20201509
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Laboratory evaluation of SARS-CoV-2 antibodies: detectable IgG up to 20 weeks post infection
Louise J. Robertson, Julie S. Moore, Kevin Blighe, Kok Yew Ng, Nigel Quinn, Fergal Jennings, Gary Warnock, Peter Sharpe, Mark Clarke, Kathryn Maguire, Sharon Rainey, Ruth Price, William Burns, Amanda Kowalczyk, Agnes Awuah, Sara McNamee, Gayle Wallace, David Hunter, Steve Segar, Connie Chao Shern, M. Andrew Nesbit, James McLaughlin, Tara Moore
medRxiv 2020.09.29.20201509; doi: https://doi.org/10.1101/2020.09.29.20201509

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (190)
  • Epidemiology (5216)
  • Forensic Medicine (3)
  • Gastroenterology (194)
  • Genetic and Genomic Medicine (750)
  • Geriatric Medicine (77)
  • Health Economics (212)
  • Health Informatics (694)
  • Health Policy (352)
  • Health Systems and Quality Improvement (223)
  • Hematology (98)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5816)
  • Intensive Care and Critical Care Medicine (356)
  • Medical Education (102)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (758)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (475)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (93)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (139)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (854)
  • Public and Global Health (1993)
  • Radiology and Imaging (344)
  • Rehabilitation Medicine and Physical Therapy (157)
  • Respiratory Medicine (283)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (75)
  • Surgery (108)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)